Regulatory Standing Sample Clauses

Regulatory Standing. I certify to TIPS for the proposal attached that my company is in good standing with all governmental agencies Xxxxx state that regulate any part of our business operations. If not, please explain in the next attribute question. Yes 8 Regulatory Standing Regulatory Standing explanation of no answer on previous question. No response
Sample 1Sample 2Sample 3See All (90)
AutoNDA by SimpleDocs
Regulatory Standing. The Issuer will not, and will not cause or permit any Issuer Subsidiary to, take or cause to be taken any action which could reasonably be expected to result in either (a) a Project losing its QF status, (b) the Issuer, either Project or either Project Company ceasing to hold any of the exemptions from regulation provided under 18 C.F.R. §§ 292.601(c) including the exception from Sections 205 and 206 of the FPA, as applicable, set forth in §292.601(c)(1), 292.602(b) and 292.602(c), (c) any disapproval, rejection, suspension, other action adverse to the continued effectiveness of a PPA or Interconnection Agreement by the FERC or the Public Utilities Commission of Oregon or Idaho, as applicable, (d) any termination, revocation, suspension, or other action adverse to the continued effectiveness of the MBR Authority held by the USG Oregon Project Company, or (e) any Secured Party or any “affiliate” (as that term is defined in PUHCA) of any Secured Party, solely as a result of the Issuer’s or any Issuer Subsidiary’s or any of their Affiliates’ actions relating to the ownership, leasing or operation of a Project, the sale of electricity therefrom or the entering into of any Financing Document or any transaction contemplated thereby, becoming subject to, or not exempt from regulation under, PUHCA or the FPA, other than any such regulation that may result from the exercise by any Secured Party of its remedies under the Financing Documents.
Sample 1
Regulatory Standing. The Issuer will not take or cause to be taken any action which could reasonably be expected to result in either (a) the Project losing its QF status, or the Issuer ceasing to hold any of the exemptions from regulation provided under 18 C.F.R. §§ 292.601(c) including the exception from Sections 205 and 206 of the FPA set forth in §292.601(c)(1), 292.602(b) and 292.602(c), or would cause any disapproval, rejection, suspension, other action adverse to the continued effectiveness of the PPA or the Interconnection Agreement by the FERC or the Public Utilities Commission of Nevada, or (b) any Secured Party or any “affiliate” (as that term is defined in PUHCA) of any Secured Party, solely as a result of the Issuer’s or any of their Affiliates’ actions relating to the ownership, leasing or operation of the Project, the sale of electricity therefrom or the entering into of any Financing Document or any transaction contemplated thereby, becoming subject to, or not exempt from regulation under, PUHCA or the FPA, other than any such regulation that may result from the exercise by any Secured Party of its remedies under the Financing Documents.
Sample 1
Regulatory Standing. Regulatory Standing explanation of no answer on previous question. Emerald Coast Vision Aids is in good standing with all businesses and governmental agencies
Sample 1

Related to Regulatory Standing

  • Regulatory Status The Local Manager is authorised and regulated by the Financial Services Authority (the “FSA”), the UK supervisory authority whose registered office is at 25 The North Colonnade, Canary Xxxxx, Xxxxxx, Xxxxxx Xxxxxxx X00 0XX.

  • Regulatory Filings NYISO and Connecting Transmission Owner shall file this Agreement (and any amendment hereto) with the appropriate Governmental Authority, if required. Any information related to studies for interconnection asserted by Developer to contain Confidential Information shall be treated in accordance with Article 22 of this Agreement and Attachment F to the ISO OATT. If the Developer has executed this Agreement, or any amendment thereto, the Developer shall reasonably cooperate with NYISO and Connecting Transmission Owner with respect to such filing and to provide any information reasonably requested by NYISO and Connecting Transmission Owner needed to comply with Applicable Laws and Regulations.

  • Regulatory Authority If any regulatory authority having jurisdiction (or any successor boards or agencies), a court of competent jurisdiction or other Governmental Authority with the appropriate jurisdiction (collectively, the ''Regulatory Body'') issues a rule, regulation, law or order that has the effect of cancelling, changing or superseding any term or provision of this Agreement (the ''Regulatory Requirement''), then this Agreement will be deemed modified to the extent necessary to comply with the Regulatory Requirement. Notwithstanding the foregoing, if a Regulatory Body materially modifies the terms and conditions of this Agreement and such modification(s) materially affect the benefits flowing to one or both of the Parties, as determined by either of the Parties within twenty (20) business days of the receipt of the Agreement as materially modified, the Parties agree to attempt in good faith to negotiate an amendment or amendments to this Agreement or take other appropriate action(s) so as to put each Party in effectively the same position in which the Parties would have been had such modification not been made. In the event that, within sixty (60) days or some other time period mutually agreed upon by the Parties after such modification has been made, the Parties are unable to reach agreement as to what, if any, amendments are necessary and fail to take other appropriate action to put each Party in effectively the same position in which the Parties would have been had such modification not been made, then either Party shall have the right to unilaterally terminate this Agreement forthwith.

  • Regulatory Authorities Except as described in the Registration Statement, the General Disclosure Package or the Prospectus, each of the Company and its subsidiaries: (a) is and at all times has been in material compliance with all statutes, rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company (“Applicable Laws”); (b) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any other federal, state or foreign governmental authority having authority over the Company (“Governmental Authority”) alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”); (c) possesses all Authorizations and such Authorizations are valid and in full force and effect and are not in material violation of any term of any such Authorizations; (d) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Authority or third party alleging that any product, operation or activity is in violation of any Applicable Laws or Authorizations and have no knowledge that any such Governmental Authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (e) has not received notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Authority is considering such action; and (f) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission). The studies, tests and preclinical and clinical trials material to the Company and its subsidiaries taken as a whole, and conducted by or on behalf of the Company and each of its subsidiaries, were and, if still pending, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Applicable Laws and Authorizations, including, without limitation, the Federal Food, Drug and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package or the Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, the Company is not aware of any studies, tests or trials the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus when viewed in the context in which such results are described and the clinical state of development; and neither the Company nor any of its subsidiaries has received any notices or correspondence from any Governmental Authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company or any of its subsidiaries that are material to the Company and its subsidiaries taken as a whole.

Time is Money Join Law Insider Premium to draft better contracts faster.